EPIX - ESSA Pharma Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development5,726.36613,060.2014,975.928
Selling General and Administrative5,925.5046,581.9635,352.274
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-11,651.87-19,642.164-10,328.202
Income from Continuing Operations
Total Other Income/Expenses Net7,269.2496,653.648651.615
Earnings Before Interest and Taxes-4,382.621-12,988.516-9,676.587
Interest Expense---
Income Before Tax-4,382.621-12,988.516-9,676.587
Income Tax Expense340.757151.272-
Minority Interest---
Net Income From Continuing Ops-4,723.378-13,139.788-9,676.587
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-4,723.378-13,139.788-9,676.587
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-4,723.378-13,139.788-9,676.587